An observational study in Anxiety Disorders, Depressive Disorder and Obsessive-Compulsive Disorder, sponsored by IRCCS Centro Neurolesi Bonino Pulejo. Enrolling by invitation at 1 site in Italy. Open to participants aged 12 Years to 20 Years. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by IRCCS Centro Neurolesi Bonino Pulejo · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Obsessive-Compulsive Disorder with a site in Italy — 5 open to participants now, 6 under way, none of them phase 3. Obsessive-Compulsive Disorder · Italy.
Among the 14 studies in Obsessive-Compulsive Disorder with a site in Italy, this one is the only one that started in 2025, is one of 4 observational ones, and was the 11th registered.
637 studies on the registry are indexed under Obsessive-Compulsive Disorder; 167 are open to participants now.
Browse Obsessive-Compulsive Disorder studies →5 of the 14 studies in Obsessive-Compulsive Disorder with a site in Italy are open now. Recruiting first, the newest first:
IRCCS Centro San Giovanni di Dio Fatebenefratelli · Sites in Italy
Ages 18–45
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Sites in Italy
Ages 18+
ASST Fatebenefratelli Sacco · Sites in Italy
Ages 18–65
Carmen Concerto · Sites in Italy
Ages 18–55 · Healthy volunteers
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 120 Obsessive-Compulsive Disorder studies recruiting now, 30 (25%) set no upper age limit and 82 (68%) stop at 75 or younger; 28 take children under 18; 19 take healthy volunteers.
This study: 12 Years to 20 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 2 · Phase 4 3
First in 2008; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 192 is above the median of 133 across 86 observational studies indexed under Obsessive-Compulsive Disorder.
Median enrollment 37 across the 10 interventional studies, 342 across the 4 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 14 have an industry lead sponsor. The 10 most frequent:
IRCCS Centro Neurolesi Bonino Pulejo is the lead sponsor of 67 studies on the registry; 30 are open to participants now.
IRCCS Centro Neurolesi Bonino Pulejo has 1 study filed under Obsessive-Compulsive Disorder — fewer than ten, so there is no comparison to draw.
2 of the studies in Obsessive-Compulsive Disorder with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07488663ASST Fatebenefratelli SaccoMODELING OBSESSIVE COMPULSIVE DISORDER AND EXPLORING TREATMENT RESPONSE USING INNOVATIVE THERAPIES AND STEM CELLS | 2027-01 |
| NCT06724029Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaNeurosurgical Outcome Network | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Obsessive-Compulsive Disorder with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This observational study aims to evaluate the effectiveness of two different psychotherapy approaches-Cognitive Behavioral Therapy (CBT) and Brief Strategic Therapy (BST)-in treating adolescents with psychological disorders. The study will follow adolescents aged 12 to 20 who are receiving psychotherapy as part of their routine clinical care at the IRCCS Centro Neurolesi "Bonino-Pulejo" in Messina, Italy. Participants will not be randomly assigned to a treatment; instead, their natural clinical path will be observed. Data will be collected through standardized psychological assessments at the beginning, during, and after the therapy, as well as at follow-ups at 3 and 9 months. The goal is to understand which therapeutic model is more effective in improving symptoms, quality of life, and self-esteem in adolescents, and how individual and family factors influence treatment outcomes.
This is a 5-year observational study evaluating the effectiveness and clinical characteristics of two psychotherapy approaches-Cognitive Behavioral Therapy (CBT) and Brief Strategic Therapy (BST)-in adolescents with psychiatric disorders. Patients aged 12 to 20 receiving care at the IRCCS Centro Neurolesi "Bonino-Pulejo" will be followed according to standard clinical practice, without random assignment. Psychopathological symptoms, self-esteem, and quality of life will be assessed at multiple time points (baseline, mid-treatment, end of treatment, and 3- and 9-month follow-ups) using standardized psychological tools. A propensity score matching method will be applied to reduce selection bias between treatment groups. The study also aims to identify predictors of treatment response and explore the influence of clinical and family-related factors on therapeutic outcomes. Data will be analyzed using both intra-group and inter-group statistical comparisons.
637 studies on the registry are indexed under Obsessive-Compulsive Disorder; 167 are open to participants now.
This study's planned enrollment of 192 is above the median of 133 across 86 observational studies indexed under Obsessive-Compulsive Disorder.
Browse Obsessive-Compulsive Disorder studies →IRCCS Centro Neurolesi Bonino Pulejo is the lead sponsor of 67 studies on the registry; 30 are open to participants now.
Compared within Obsessive-Compulsive Disorder, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Adolescents aged 12 to 20 years with clinically diagnosed psychiatric disorders, referred to the Child and Adolescent Psychiatry Unit at IRCCS Centro Neurolesi "Bonino-Pulejo" in Messina, Italy. All participants will be receiving psychotherapy (CBT or BST) as part of standard clinical care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receiving Cognitive Behavioral Therapy (CBT) as part of routine clinical care for adolescent psychopathology.
Participants receiving Brief Strategic Therapy (BST) as part of routine clinical care for adolescent psychopathology.
Child Behavior Checklist (CBCL)
The Child Behavior Checklist (CBCL) is a standardized parent-report questionnaire used to assess a wide range of emotional and behavioral problems in children. Higher scores indicate greater levels of emotional and behavioral difficulties.
Time frame: Baseline, Month 3, Month 6, Month 9, and Month 12
SAFA General Screening Scales
The SAFA (Self Administrated Psychiatric Scales for Youths and Adolescents) is a comprehensive set of standardized self-report questionnaires used to assess emotional and psychiatric symptoms in children and adolescents aged 8 to 18 years. The full battery includes six scales: * SAFA-A (Anxiety) * SAFA-D (Depression) * SAFA-O (Obsessive-Compulsive Symptoms) * SAFA-S (Somatic Complaints) * SAFA-P (Psychogenic Psychotic Symptoms) * SAFA-F (Eating Disorders) Each scale produces a raw score, which is then converted into a standardized score. Total scores for each domain range approximately from 0 to 100, although precise ranges vary slightly by scale and age group. Higher scores reflect more severe emotional or psychological difficulties, i.e., a worse outcome.
Time frame: Baseline, Month 3, Month 6, Month 9, and Month 12
Personality Inventory for DSM (PID)
The Personality Inventory for DSM-5 (PID-5) is a standardized self-report instrument developed to assess maladaptive personality traits aligned with the DSM-5 alternative model for personality disorders. It includes 220 items, rated on a 4-point Likert scale (0 = Very False or Often False; 3 = Very True or Often True), and provides scores on five broad domains: * Negative Affectivity * Detachment * Antagonism * Disinhibition * Psychoticism Scores range from 0 to 660 (sum of all item scores), although domain and facet scores are typically reported separately. Higher scores reflect more severe or dysfunctional personality traits (i.e., a worse outcome).
Time frame: Baseline, Month 3, Month 6, Month 9, and Month 12
Columbia-Suicide Severity Rating Scale (C-SSRS)
The Columbia-Suicide Severity Rating Scale (C-SSRS) is a structured clinical interview used to assess suicidal ideation and behavior. It includes subscales for suicidal thoughts, intent, plans, preparatory behavior, and actual suicide attempts. Each item is scored individually; for example: * Suicidal ideation severity scale: 0 (no ideation) to 5 (active ideation with specific plan and intent), * Behavior subscale: binary indicators (yes/no) of actual, aborted, or interrupted attempts. Higher scores indicate greater severity of suicide risk and behavior (i.e., a worse outcome).
Time frame: Baseline, Month 3, Month 6, Month 9, and Month 12
Toronto Alexithymia Scale (TAS-20)
The Toronto Alexithymia Scale (TAS-20) is a standardized self-report instrument designed to assess difficulties in identifying and describing emotions, and externally oriented thinking. It consists of 20 items, each rated on a 5-point Likert scale (1 = Strongly disagree to 5 = Strongly agree). Total scores range from 20 to 100, with higher scores indicating greater levels of alexithymia (i.e., worse emotional awareness).
Time frame: Baseline, Month 3, Month 6, Month 9, and Month 12
Barratt Impulsiveness Scale (BIS-11)
The Barratt Impulsiveness Scale - Version 11 (BIS-11) is a widely used self-report questionnaire designed to assess impulsivity as a personality trait. It consists of 30 items, rated on a 4-point Likert scale from 1 (Rarely/Never) to 4 (Almost Always/Always). Total scores range from 30 to 120, with higher scores indicating greater impulsivity (i.e., a worse outcome).
Time frame: Baseline, Month 3, Month 6, Month 9, and Month 12
Difficulties in Emotion Regulation Scale - Short Form (DERS-SF)
The DERS-SF (Difficulties in Emotion Regulation Scale - Short Form) is an 18-item self-report instrument that assesses difficulties in emotion regulation. Each item is scored on a 5-point Likert scale from 1 (Almost Never) to 5 (Almost Always). Total scores range from 18 to 90. Higher scores indicate greater difficulties in emotion regulation (i.e., a worse outcome).
Time frame: Baseline, Month 3, Month 6, Month 9, and Month 12
Rosenberg Self-Esteem Scale (RSES)
The Rosenberg Self-Esteem Scale (RSES) is a widely used 10-item self-report questionnaire designed to measure global self-esteem in adolescents and adults. Each item is rated on a 4-point Likert scale (1 = Strongly Disagree to 4 = Strongly Agree), with both positively and negatively worded items. Total scores range from 10 to 40, with higher scores indicating higher self-esteem (i.e., a better outcome). Scores below 15 may indicate problematic low self-esteem.
Time frame: Baseline, Month 3, Month 6, Month 9, and Month 12
Wechsler Intelligence Scale for Children (WISC-IV) / Raven's Progressive Matrices
Cognitive functioning is assessed at baseline using one or both of the following standardized instruments: * The Wechsler Intelligence Scale for Children - Fourth Edition (WISC-IV), a widely used clinical tool for measuring verbal comprehension, perceptual reasoning, working memory, and processing speed. The Full Scale IQ (FSIQ) score ranges from 40 to 160, with higher scores indicating greater cognitive ability. * The Raven's Progressive Matrices is a non-verbal test of abstract reasoning and fluid intelligence. Standard scores range from 60 to 140, depending on the version and age norms. Higher scores indicate higher cognitive performance. Only participants with IQ ≥ 80 (as determined by one of the above instruments) are included in the study.
Time frame: Baseline
Depression Anxiety Stress Scales - Short Version (DASS-21)
The DASS-21 (Depression Anxiety Stress Scales - Short Version) is a self-report questionnaire designed to measure negative emotional states across three domains: depression, anxiety, and stress. It consists of 21 items, with 7 items per subscale. Each item is rated on a 4-point Likert scale from 0 (Did not apply to me at all) to 3 (Applied to me very much or most of the time). Subscale scores range from 0 to 21, and are commonly multiplied by 2 to obtain scores equivalent to the full DASS-42 (range: 0 to 42 per subscale). Higher scores indicate more severe symptoms (i.e., a worse outcome).)
Time frame: Baseline, Month 3, Month 6, Month 9, and Month 12
WHO Quality of Life Questionnaire - Brief (WHOQOL-BREF)
The WHOQOL-BREF is a validated, 26-item self-report questionnaire developed by the World Health Organization to assess an individual's perceived quality of life. It includes four domains: * Physical Health * Psychological Health * Social Relationships * Environment Each item is rated on a 5-point Likert scale, and domain scores are transformed to a scale from 0 to 100, where higher scores indicate better quality of life (i.e., a better outcome). The WHOQOL-BREF has been used across cultures and is suitable for both clinical and general populations.
Time frame: Baseline, Month 3, Month 6, Month 9, and Month 12
Session Rating Scale (SRS)
The Session Rating Scale (SRS) is a 4-item self-report measure used to assess the therapeutic alliance at the end of each therapy session. Each item is rated on a visual analog scale from 0 to 10, yielding a total score ranging from 0 to 40. The four dimensions assessed are: relationship, goals and topics, approach or method, and overall alliance. Higher scores indicate a stronger therapeutic alliance (i.e., a better outcome). Scores below 36 may indicate a need to address ruptures in the alliance.
Time frame: Each session over 10 sessions (approximately 10 weeks)
Outcome Rating Scale (ORS)
The Outcome Rating Scale (ORS) is a 4-item self-report tool designed to measure a client's perception of change and progress in therapy. It evaluates functioning in four areas: individual (personal well-being), interpersonal (close relationships), social (work/school), and general well-being. Each item is scored from 0 to 10, resulting in a total score ranging from 0 to 40. Higher scores reflect greater perceived well-being and positive clinical change (i.e., a better outcome).
Time frame: Each session over 10 sessions (approximately 10 weeks)
Started Apr 2025 (actual). Primary completion is estimated for Dec 2030, 68 months after the start.
Of 27 observational studies under Obsessive-Compulsive Disorder, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 84. This study's planned 68 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Obsessive-Compulsive Disorder →
IRCCS Centro Neurolesi Bonino Pulejo